Novo Nordisk A/S (NYSE:NVO) Rating Increased to Buy at UBS Group

UBS Group upgraded shares of Novo Nordisk A/S (NYSE:NVO - Free Report) from a sell rating to a buy rating in a research report sent to investors on Wednesday morning,Benzinga reports.

A number of other equities analysts also recently weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday. StockNews.com cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Finally, BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $140.20.

Novo Nordisk A/S Stock Up 2.7 %

Shares of NVO stock traded up $2.29 on Wednesday, hitting $85.63. 9,192,861 shares of the stock were exchanged, compared to its average volume of 7,559,210. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $384.27 billion, a P/E ratio of 27.71, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The business has a 50-day moving average of $101.94 and a 200 day moving average of $120.27.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors have recently bought and sold shares of NVO. Rhumbline Advisers lifted its holdings in Novo Nordisk A/S by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 60,974 shares of the company's stock valued at $8,703,000 after purchasing an additional 270 shares during the last quarter. Gryphon Financial Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 56.6% during the 2nd quarter. Gryphon Financial Partners LLC now owns 3,086 shares of the company's stock worth $440,000 after buying an additional 1,116 shares during the period. Headlands Technologies LLC grew its stake in Novo Nordisk A/S by 33.5% in the 2nd quarter. Headlands Technologies LLC now owns 22,323 shares of the company's stock valued at $3,186,000 after buying an additional 5,607 shares during the last quarter. MGO One Seven LLC raised its holdings in Novo Nordisk A/S by 22.4% in the 2nd quarter. MGO One Seven LLC now owns 19,799 shares of the company's stock valued at $2,826,000 after acquiring an additional 3,629 shares during the period. Finally, SP Asset Management LLC acquired a new stake in Novo Nordisk A/S during the second quarter worth approximately $321,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.